Crystal Conn

Title: Crystal Conn: Innovator in Cancer Treatment

Introduction

Crystal Conn is a prominent inventor based in Oakland, CA. She has made significant contributions to the field of cancer treatment, particularly in understanding how tumors adapt to stress. With a total of 2 patents, her work focuses on innovative therapeutic strategies that target cancer cell survival mechanisms.

Latest Patents

One of Crystal Conn's latest patents addresses cancer treatment targeted to tumor adaptive responses to protein synthesis stress. In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2α axis of the UPR adaptive response. Agents that disrupt PERK-eIF2α pathways can lead to cancer cell death from uncontrolled growth. For example, ISRIB and its derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally, PTEN loss and activation of Myc provide a diagnostic marker that enables better prognosis and the selection of amenable treatments.

Career Highlights

Crystal Conn is affiliated with the University of California, where she continues her research and development in cancer therapies. Her innovative approaches have the potential to change the landscape of cancer treatment and improve patient outcomes.

Collaborations

Some of her notable coworkers include Davide Ruggero and Hao Nguyen, who contribute to her research efforts and collaborative projects.

Conclusion

Crystal Conn is a trailblazer in cancer treatment innovation, with her patents paving the way for new therapeutic strategies. Her work exemplifies the importance of research in combating cancer and improving patient care.